Center-Authored Papers

Filters: Author is Park, Julie R  [Clear All Filters]
C
Campbell K, Gastier-Foster JM, Mann M, Naranjo AH, Van Ryn C, Bagatell R, Matthay KK, London WB, Irwin MS, Shimada H et al..  2017.  Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.. Cancer. Abstract
E
Erbe AK, Wang W, Reville PK, Carmichael L, Kim KM, Mendonca EA, Song Y, Hank JA, London WB, Naranjo A et al..  2017.  HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.. FRONTIERS IN IMMUNOLOGY. 8 Abstract
F
Fisher BT, Zaoutis TE, Park JR, Bleakley M, Englund JA, Kane C, Arceci RJ, Guinan E, Smith FO, Luan X et al..  2012.  Galactomannan Antigen Testing for Diagnosis of Invasive Aspergillosis in Pediatric Hematology Patients.. Journal of the Pediatric Infectious Diseases Society. 1(2):103-111. Abstract
G
Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, Bleakley M, Brown C, Mgebroff S, Spratt K et al..  2017.  Intent to treat leukemia remission by CD19CAR T cells of defined formulation and dose in children and young adults.. Blood. Abstract
I
Irwin MS, Park JR.  2015.  Neuroblastoma: paradigm for precision medicine.. Pediatric clinics of North America. 62(1):225-56. Abstract
K
Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L et al..  2013.  Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.. The lancet oncology. 14(10):999-1008. Abstract
Künkele A, Taraseviciute A, Finn LS, Johnson AJ, Berger C, Finney O, Chang CA, Rolczynski LS, Brown C, Mgebroff S et al..  2016.  Preclinical Assessment of CD171-Directed CAR T Cell Adoptive Therapy For Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
L
Leary SES, Park JR, Reid JM, Ralya AT, Baruchel S, Wu B, Roberts TPL, Liu X, Minard CG, Fox E et al..  2017.  Pediatric phase 1 trial and pharmacokinetic study of trebananib in relapsed solid tumors ADVL1115: A Children's Oncology Group phase 1 consortium report.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
M
Meany HJ, Seibel NL, Krailo M, Villaluna D, Chen Z, Gaynon P, Neglia JP, Park JR, Hutchinson R, Sato JK et al..  2015.  Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group.. Journal of immunotherapy (Hagerstown, Md. : 1997). 38(7):299-305. Abstract
Meany HJ, London WB, Ambros PF, Matthay KK, Monclair T, Simon T, Garaventa A, Berthold F, Nakagawara A, Cohn SL et al..  2014.  Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project.. Pediatric blood & cancer. Abstract
Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes S-E-N, Diccianni MB, Sondel PM et al..  2017.  Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.. The Lancet. Oncology. Abstract
P
Parikh NS, Howard SC, Chantada G, Israels T, Khattab M, Alcasabas P, Lam CG, Faulkner L, Park JR, London WB et al..  2015.  SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings.. Pediatric blood & cancer. Abstract
Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG et al..  2017.  Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. :JCO2016720177. Abstract
Pinto N, Park JR, Murphy E, Yearley J, McClanahan T, Annamalai L, Hawkins DS, Rudzinski ER.  2017.  Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors.. Pediatric blood & cancer. Abstract
Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR et al..  2015.  Advances in Risk Classification and Treatment Strategies for Neuroblastoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(27):3008-3017. Abstract
R
Raccor BS, Claessens AJ, Dinh JC, Park JR, Hawkins DS, Thomas SS, Makar KW, McCune JS, Totah RA.  2012.  Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation: in vitro and in vivo investigations.. Drug metabolism and disposition: the biological fate of chemicals. 40(1):54-63. Abstract
S
Stricker TP, Morales La Madrid A, Chlenski A, Guerrero L, Salwen HR, Gosiengfiao Y, Perlman EJ, Furman W, Bahrami A, Shohet JM et al..  2014.  Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter™ system.. Molecular oncology. 8(3):669-78. Abstract
T
Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE, Chang AN, Frazier J, Chau NB, Loboda A, Linsley PS et al..  2012.  Functional genomics identifies therapeutic targets for MYC-driven cancer.. Proceedings of the National Academy of Sciences of the United States of America. 109(24):9545-50. Abstract
W
Wang LL, Suganuma R, Ikegaki N, Tang X, Naranjo A, McGrady P, London WB, Hogarty MD, Gastier-Foster JM, Look TA et al..  2013.  Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Oncology Group.. Cancer. Abstract